Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date Sort descending | Purpose |
|---|---|---|---|---|---|
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | PAR-23-041 | NIDA | The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant… More | ||
| Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | PAR-23-169 | NIAID | The purpose of this reissued Funding Opportunity Announcement (FOA) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection… More | ||
| International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) | RFA-AI-23-023 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-… More | ||
| Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) | PAR-23-117 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research… More | ||
| Centers for AIDS Research (P30 Clinical Trial Not Allowed) | PAR-23-116 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance… More | ||
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | RFA-DA-24-007 | NIDA | oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of… More | ||
| NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed) | PAR-23-109 | NIAID | The purpose of the MSPP is to develop a diverse pool of combined-degree students (e.g., MD/PhD, DDS/PhD, DVM/PhD) who have conducted their PhD dissertation research at research laboratories in the… More | ||
| Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) | RFA-DA-24-001 | NIDA | This Funding Opportunity Announcement (FOA) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND… More | ||
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed) | RFA-DA-25-011 | NIDA | This broad RFA will support exploratory studies addressing mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including HAND) in the context of SUDs. | ||
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) | RFA-DA-25-014 | NIDA | The goal of this funding opportunity announcement is to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD, then use those molecular profiles and… More |